Relative Bioavailability Study of HU6

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

November 15, 2024

Study Completion Date

December 15, 2024

Conditions

Healthy

Interventions

DRUG

HU6 450 mg Tablet

new 450 mg tablet test formulation

DRUG

HU6 150 mg Capsules x 3 (Total dose = 450 mg)

150 mg capsule reference formulation (3 x 150 mg).

Trial Locations (1)

Nucleus Network, Saint Paul

All Listed Sponsors

lead

Rivus Pharmaceuticals, Inc.

INDUSTRY

NCT06486558 - Relative Bioavailability Study of HU6 | Biotech Hunter | Biotech Hunter